EUVIMEDEUVIMED entdecken
Übersichtsarbeit

State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care

Nicole Baranda Balmaceda, Angelica Petrillo, Mridula Krishnan, Joseph J Zhao, Sunnie Kim, Kelsey A Klute, Raghav Sundar iD

American Society of Clinical Oncology Educational Book · 2024-06 · 44 (3)

DOI: 10.1200/edbk_431060 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2024-06. Verfasst von Nicole Baranda Balmaceda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Stomach Neoplasms, Precision Medicine, Biomarkers, Tumor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 170 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastroesophageal cancers (GECs) represent a significant clinical challenge. For early resectable GEC, the integration of immune checkpoint inhibitors into the perioperative chemotherapy and chemoradiation treatment paradigms are being explored and showing promising results. Frontline management of metastatic GEC is exploring the role of targeted therapies beyond PD-1 inhibitors, including anti–human epidermal growth factor receptor 2 agents, Claudin 18.2 inhibitors, and FGFR2 inhibitors, which have shown considerable efficacy in recent trials. Looking ahead, ongoing trials and emerging technologies such as bispecific antibodies, antibody-drug conjugates, and adoptive cell therapies like chimeric antigen receptor T cells are expected to define the future of GEC management. These advancements signify a paradigm shift toward personalized and immunotherapy-based approaches, offering the potential for improved outcomes and reduced toxicity for patients with GEC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsStomach NeoplasmsPrecision MedicineBiomarkers, TumorHumansMolecular Targeted TherapyImmunotherapyImmune Checkpoint InhibitorsCombined Modality Therapy

Substanzen

Biomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
  • Medical Oncology Unit, Ospedale del Mare, Naples, Italy.
  • Division of Oncology and Hematology, Department of Medicine, University of Nebraska Medical Center, Omaha, NB.
  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Department of Hematology-Oncology, National University Cancer Institute, Singapore.
  • Department of Medicine, National University Hospital, Singapore, Singapore.

ORCID-Profile: Raghav Sundar

Zitieren

APA

Balmaceda, N. B., Petrillo, A., Krishnan, M., Zhao, J. J., Kim, S., Klute, K. A., & Sundar, R. (2024). State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. American Society of Clinical Oncology Educational Book, 44(3). https://doi.org/10.1200/edbk_431060

Vancouver

Balmaceda NB, Petrillo A, Krishnan M, Zhao JJ, Kim S, Klute KA, et al. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. American Society of Clinical Oncology Educational Book. 2024;44(3). doi:10.1200/edbk_431060

BibTeX
@article{Balmaceda2024,
  author = {Balmaceda, Nicole Baranda and Petrillo, Angelica and Krishnan, Mridula and Zhao, Joseph J and Kim, Sunnie and Klute, Kelsey A and Sundar, Raghav},
  title = {State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2024},
  volume = {44},
  number = {3},
  doi = {10.1200/edbk_431060}
}
Kostenlos starten →